4,736 Shares in Illumina, Inc. $ILMN Bought by Landscape Capital Management L.L.C.

Key Points

• Landscape Capital Management L.L.C. acquired a new stake in Illumina, Inc., purchasing 4,736 shares valued at approximately $376,000 during the 1st quarter.
• Institutional investors now hold 89.42% of Illumina's stock, with significant increases in holdings reported by firms like BNP Paribas Financial Markets and Ieq Capital LLC.
• Analysts have mixed ratings on Illumina, with updates including a price target increase from Robert W. Baird to $105.00 and a downgrade from Citigroup to a "strong sell" rating with a target of $80.00.

Landscape Capital Management L.L.C. bought a new position in Illumina, Inc. (NASDAQ:ILMN - Free Report) in the first quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 4,736 shares of the life sciences company's stock, valued at approximately $376,000.

A number of other hedge funds also recently bought and sold shares of ILMN. Lido Advisors LLC lifted its position in Illumina by 18.1% in the 4th quarter. Lido Advisors LLC now owns 3,392 shares of the life sciences company's stock worth $453,000 after buying an additional 521 shares during the last quarter. Keel Point LLC bought a new stake in Illumina in the 4th quarter worth approximately $204,000. BNP Paribas Financial Markets lifted its position in Illumina by 100.5% in the 4th quarter. BNP Paribas Financial Markets now owns 590,287 shares of the life sciences company's stock worth $78,880,000 after buying an additional 295,896 shares during the last quarter. BNP Paribas bought a new stake in Illumina in the 4th quarter worth approximately $302,000. Finally, Benjamin Edwards Inc. bought a new stake in Illumina in the 4th quarter worth approximately $541,000. Institutional investors own 89.42% of the company's stock.

Illumina Trading Down 1.8%

Shares of ILMN traded down $1.75 during mid-day trading on Wednesday, hitting $96.07. 1,163,473 shares of the company's stock traded hands, compared to its average volume of 1,426,234. The company has a quick ratio of 1.41, a current ratio of 1.81 and a debt-to-equity ratio of 0.66. Illumina, Inc. has a 1 year low of $68.70 and a 1 year high of $156.66. The firm has a market capitalization of $14.77 billion, a P/E ratio of 12.16, a PEG ratio of 2.25 and a beta of 1.43. The business's 50-day moving average price is $99.47 and its 200-day moving average price is $88.58.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its earnings results on Thursday, July 31st. The life sciences company reported $1.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.17. Illumina had a return on equity of 28.93% and a net margin of 29.36%.The firm had revenue of $1.06 billion for the quarter, compared to analysts' expectations of $1.12 billion. During the same period in the previous year, the firm earned $0.36 earnings per share. The business's revenue was down 4.8% compared to the same quarter last year. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. As a group, sell-side analysts forecast that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently weighed in on ILMN. Daiwa Capital Markets downgraded Illumina from an "outperform" rating to a "neutral" rating and set a $94.00 target price for the company. in a research report on Tuesday, August 12th. Citigroup downgraded Illumina from a "hold" rating to a "strong sell" rating and lowered their price objective for the company from $85.00 to $80.00 in a research report on Wednesday, July 9th. Piper Sandler lowered their price objective on Illumina from $190.00 to $185.00 and set an "overweight" rating for the company in a research report on Thursday, May 15th. Wall Street Zen downgraded Illumina from a "buy" rating to a "hold" rating in a research report on Saturday, August 2nd. Finally, JPMorgan Chase & Co. lowered their price objective on Illumina from $120.00 to $85.00 and set a "neutral" rating for the company in a research report on Friday, May 9th. Six analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $123.06.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.